Eric Venker - 07 Jun 2023 Form 4 Insider Report for Roivant Sciences Ltd. (ROIV)

Role: President & COO
Signature: By: /s/ Jo Chen, as Attorney-in-Fact for Eric Venker
Issuer symbol: ROIV
Transactions as of: 07 Jun 2023
Net transactions value: -$1,815,473
Form type: 4
Filing time: 09 Jun 2023, 21:32:20 UTC
Previous filing: 25 May 2023
Next filing: 26 Jun 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ROIV	Common Shares	Options Exercise	$774	+201	+0.03%	$3.85	660,298	07 Jun 2023	Direct
transaction	ROIV	Common Shares	Sale	$1,980	-201	-0.03%	$9.85	660,097	07 Jun 2023	Direct	F1
transaction	ROIV	Common Shares	Options Exercise	$1,152,628	+299,384	+45%	$3.85	959,481	09 Jun 2023	Direct
transaction	ROIV	Common Shares	Sale	$2,966,895	-299,384	-31%	$9.91	660,097	09 Jun 2023	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ROIV	Stock Option (Right to Buy)	Options Exercise	$0	-201	-0%	$0.000000	15,622,568	07 Jun 2023	Common Shares	201	$3.85	Direct	F2
transaction	ROIV	Stock Option (Right to Buy)	Options Exercise	$0	-299,384	-1.9%	$0.000000	15,323,184	09 Jun 2023	Common Shares	299,384	$3.85	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (1) to this Form 4. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2023.
F2	Award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the applicable vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation).

Content

The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (1) to this Form 4. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2023.

Award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the applicable vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation).